Protara Therapeutics Inc TARA Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Davis Blaine

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

75,000

Price:

--
Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Zummo Jacqueline

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

75,000

Price:

--
Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Shefferman Jesse

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

202,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Zummo Jacqueline

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,653

Price:

$21.16
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Shefferman Jesse

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-5,069

Price:

$21.16
Sep 30, 2020 (filed on Oct 02, 2020)

Insider Name:

Opaleye Management Inc.

Ownership Type:

Indirect Ownership

Securities:

Common Stock, par value $0.001 per share

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

50,000

Price:

$16.00
Sep 24, 2020 (filed on Sep 25, 2020)

Insider Name:

Opaleye Management Inc.

Ownership Type:

Indirect Ownership

Securities:

Common Stock, par value $0.001 per share

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

200,000

Price:

$16.87
Sep 24, 2020 (filed on Sep 25, 2020)

Insider Name:

Opaleye Management Inc.

Ownership Type:

Indirect Ownership

Securities:

Common Stock, par value $0.001 per share

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

100,000

Price:

$16.87
Sep 22, 2020 (filed on Sep 23, 2020)

Insider Name:

Davis Blaine

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,481

Price:

$16.91
Sep 14, 2020 (filed on Sep 15, 2020)

Insider Name:

Marshall Randall

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-474

Price:

$20.00

Filings by filing date

Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Davis Blaine

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

75,000

Price:

--
Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Zummo Jacqueline

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

75,000

Price:

--
Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Shefferman Jesse

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

202,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Zummo Jacqueline

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,653

Price:

$21.16
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Shefferman Jesse

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-5,069

Price:

$21.16
Sep 30, 2020 (filed on Oct 02, 2020)

Insider Name:

Opaleye Management Inc.

Ownership Type:

Indirect Ownership

Securities:

Common Stock, par value $0.001 per share

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

50,000

Price:

$16.00
Sep 24, 2020 (filed on Sep 25, 2020)

Insider Name:

Opaleye Management Inc.

Ownership Type:

Indirect Ownership

Securities:

Common Stock, par value $0.001 per share

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

200,000

Price:

$16.87
Sep 24, 2020 (filed on Sep 25, 2020)

Insider Name:

Opaleye Management Inc.

Ownership Type:

Indirect Ownership

Securities:

Common Stock, par value $0.001 per share

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

100,000

Price:

$16.87
Sep 22, 2020 (filed on Sep 23, 2020)

Insider Name:

Davis Blaine

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,481

Price:

$16.91
Sep 14, 2020 (filed on Sep 15, 2020)

Insider Name:

Marshall Randall

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-474

Price:

$20.00

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	345 Park Avenue South, 3Rd Floor NEW YORK NY 10010
Tel:	1-646-8440337
Website:	https://protaratx.com
IR:	See website

Key People

Luke M. Beshar Chairman of the Board	Jesse Shefferman President, Chief Executive Officer, Director	Blaine Davis Chief Financial Officer
Jacqueline Zummo Chief Scientific Operations Officer

Business Overview

Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Its product pipeline includes TARA 002 and IV choline chloride for injection. TARA 002 is its lead program focused on the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).

Financial Overview

For the nine months ended 30 September 2020, ProtaraTherapeutics Inc revenues was not reported. Net lossincreased 88% to $25.2M. Higher net loss reflectsStock-based Compensation in SGA increase from $744K to$6.8M (expense), General and administrative - Balancing vincrease of 59% to $10.3M (expense), Research anddevelopment - Balancing val increase of 26% to $7.8M(expense).

Employees:	8 as of Mar 10, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$58.14M as of Sep 30, 2020
Annual revenue (TTM):	$0.00M as of Sep 30, 2020
EBITDA (TTM):	-$28.08M as of Sep 30, 2020
Net annual income (TTM):	-$26.78M as of Sep 30, 2020
Free cash flow (TTM):	-$20.15M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	11,211,840 as of Nov 10, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Protara Therapeutics Inc (OQ:TARA)